SHINE Technologies is supplying UK-based Blue Earth Therapeutics with a key material for a prostate cancer clinical trial, the Janesville company says.

In a recent release, SHINE announced its partnership with the business, which develops radiopharmaceutical medicines. SHINE has provided the first supply of its lutetium-177 chloride — or Ilumira — product to Blue Earth Therapeutics, for use in clinical trials evaluating a possible treatment for prostate cancer patients.

Greg Piefer, founder and CEO of SHINE, says this product is meant to “give the world access to a cleaner, safer and more cost-effective and robust source” of Lu-177 to improve care for cancer patients.

Click here to read the full article.